Literature DB >> 16195824

Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.

Barbara Sonntag1, Ludwig Kiesel, Eberhard Nieschlag, Hermann M Behre.   

Abstract

PURPOSE: To study effects of endogenous LH levels on ovarian response and outcome in ART cycles a controlled study was performed with two patient groups differing in the intensity of pituitary downregulation.
METHODS: Group I (n = 27) received 3.75 mg of the GnRH agonist triptorelin acetate depot, group II (n = 54) was given 0.1 mg triptorelin acetate daily, followed by ovarian stimulation with recombinant FSH.
RESULTS: After downregulation serum LH and FSH levels were significantly lower in group I. Patients of group I needed significantly higher FSH doses to achieve comparable levels of serum estradiol and preovulatory follicles. The number of retrieved oocytes and transferable embryos was lower in group I.
CONCLUSION: Patients with profound endogenous LH suppression by depot GnRH agonists show higher FSH stimulation dose requirements and lower oocyte number and fertilization rate, indicating a need for minimal LH activity in folliculogenesis and oocyte development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195824     DOI: 10.1007/s10815-005-5998-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  42 in total

1.  A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.

Authors:  T Dada; O Salha; H S Baillie; V Sharma
Journal:  Hum Reprod       Date:  1999-02       Impact factor: 6.918

2.  Intrafollicular content of luteinizing hormone receptor, alpha-inhibin, and aromatase in relation to follicular growth, estrous cycle stage, and oocyte competence for in vitro maturation in the mare.

Authors:  G Goudet; F Belin; J Bézard; N Gérard
Journal:  Biol Reprod       Date:  1999-05       Impact factor: 4.285

Review 3.  Is luteinizing hormone needed for optimal ovulation induction?

Authors:  Juan Balasch; Francisco Fábregues
Journal:  Curr Opin Obstet Gynecol       Date:  2002-06       Impact factor: 1.927

4.  Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH.

Authors:  G De Placido; A Mollo; C Alviggi; I Strina; M T Varricchio; A Ranieri; N Colacurci; A Tolino; M Wilding
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

5.  Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.

Authors:  M Filicori; C Flamigni; G Cognigni; P Dellai; R Arnone; A Falbo; M Capelli
Journal:  J Clin Endocrinol Metab       Date:  1993-07       Impact factor: 5.958

6.  The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.

Authors:  J Balasch; F Miró; I Burzaco; R Casamitjana; S Civico; J L Ballescá; B Puerto; J A Vanrell
Journal:  Hum Reprod       Date:  1995-07       Impact factor: 6.918

7.  Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys.

Authors:  M B Zelinski-Wooten; J S Hutchison; D L Hess; D P Wolf; R L Stouffer
Journal:  Hum Reprod       Date:  1995-07       Impact factor: 6.918

Review 8.  The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction.

Authors:  Marco Filicori; Graciela E Cognigni; Arafat Samara; Silvia Melappioni; Tiziana Perri; Barbara Cantelli; Lodovico Parmegiani; Giuseppe Pelusi; Domenico DeAloysio
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

9.  Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.

Authors:  Philippe Merviel; Jean-Marie Antoine; Emmanuelle Mathieu; Françoise Millot; Jacqueline Mandelbaum; Serge Uzan
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

Review 10.  The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.

Authors:  Zeev Shoham
Journal:  Fertil Steril       Date:  2002-06       Impact factor: 7.329

View more
  3 in total

Review 1.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 2.  Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency.

Authors:  Leonardo Rinaldi; Helmy Selman
Journal:  Int J Womens Health       Date:  2016-05-25

3.  The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.

Authors:  Ying Zhang; Wenxian Zhao; Yifan Han; Xin Chen; Shaoyuan Xu; Yueyue Hu; Honglu Diao; Changjun Zhang
Journal:  Reprod Biol Endocrinol       Date:  2022-09-19       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.